Literature DB >> 7063276

Human erythrocyte prolidase and prolidase deficiency.

F Endo, I Matsuda, A Ogata, S Tanaka.   

Abstract

Biochemical studies on human prolidase (EC 3.4.13.9) and prolidase deficiency are described. The urine sample from a 32-year-old female with prolidase deficiency was examined. Diagnosis was based on clinical features and defects of prolidase in her erythrocytes. She excreted massive amounts of iminopeptides, where three major peptides were identified; aspartyl-proline, glutamyl-proline and glycyl-proline. The prolidase was purified approximately 10,000-fold from the normal human erythrocytes through an eight step procedure. The purified enzyme consisted of two identical subunits of which the molecular weight was calculated to be 55,000. The relative cleavage rates of the enzyme for glycyl-L-proline, L-alanyl-L-proline, L-leucyl-L-proline, L-prolyl-L-proline, and glycyl-hydroxy-L-proline were 100%, 53%, 27%, 31% and 2%, respectively. The relative substrate specificity of the enzyme offers a reasonable explantation for the presence of a higher level of urinary imidodipeptides in a patient with prolidase deficiency. An attempt at erythrocyte transfusion was performed, aimed at enzyme replacement therapy. After the transfusion (erythrocytes from 800 ml of whole blood), the prolidase activity of the peripheral erythrocyte was elevated to approximately 35% of the normal values and gradually decreased (half-life, 41 days). During this period urinary peptide-bound proline was monitored, but no significant change was observed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7063276     DOI: 10.1203/00006450-198203000-00013

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  17 in total

Review 1.  Enzyme-replacement therapy: problems and prospects.

Authors:  B Rademaker; J Raber
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

2.  Biochemical basis of prolidase deficiency. Polypeptide and RNA phenotypes and the relation to clinical phenotypes.

Authors:  F Endo; A Tanoue; A Kitano; J Arata; D M Danks; C M Lapière; Y Sei; S K Wadman; I Matsuda
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

3.  Deduced amino acid sequence of human prolidase and molecular analyses of prolidase deficiency.

Authors:  F Endo; A Tanoue; A Hata; A Kitano; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

4.  Presence in human cells and tissues of two prolidases and their alteration in prolidase deficiency.

Authors:  J Butterworth; D A Priestman
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

5.  Immunochemical analysis of prolidase deficiency and molecular cloning of cDNA for prolidase of human liver.

Authors:  F Endo; A Hata; Y Indo; K Motohara; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

6.  Substrate specificity of manganese-activated prolidase in control and prolidase-deficient cultured skin fibroblasts.

Authors:  J Butterworth; D Priestman
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

7.  Correlated mutations: a hallmark of phenotypic amino acid substitutions.

Authors:  Andreas Kowarsch; Angelika Fuchs; Dmitrij Frishman; Philipp Pagel
Journal:  PLoS Comput Biol       Date:  2010-09-16       Impact factor: 4.475

8.  Relationship of cognitive performance with prolidase and oxidative stress in Alzheimer disease.

Authors:  Adalet Arikanoglu; Esref Akil; Sefer Varol; Yavuz Yucel; Hatice Yuksel; Mehmet Ugur Cevik; Yilmaz Palanci; Fatma Unan
Journal:  Neurol Sci       Date:  2013-03-12       Impact factor: 3.307

Review 9.  Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery.

Authors:  J P Bai; G L Amidon
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

10.  Prolidase deficiency: a patient without hydroxyproline-containing iminodipeptides in urine.

Authors:  S J Wysocki; R Hahnel; T Mahoney; R G Wilson; P K Panegyres
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.